GSBD vs TRAX Comparison

Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.